Results 111 to 120 of about 61,821 (260)

Trends in 25 years of antihypertensive agent utilization in Croatia – an alert for scientific community and healthcare providers

British Journal of Clinical Pharmacology, EarlyView.
Aims Hypertension is a leading modifiable risk factor for cardiovascular mortality worldwide. This study aimed to evaluate 25‐year trends in antihypertensive agent (AHA) utilization in Croatia between 2000 and 2024. Methods We conducted a national, population‐based analysis using IMS and IQVIA pharmaceutical databases.
Andrej Belančić, Marta Kučan Štiglić, Ana Jelaković, Bojan Jelaković, Dinko Vitezić   +4 more
wiley   +1 more source

Differential game in closed-loop supply chain of innovative products with double regrets of consumers. [PDF]

PLoS One
Ma Q, Peng Y, Liu Z.
europepmc   +1 more source

Trends in publicly subsidized and private access to GLP‐1 medicines indicated for type 2 diabetes in Australia, 2020–2025

British Journal of Clinical Pharmacology, EarlyView.
Aims GLP‐1 medicines provide substantial cardio‐renal benefits for type 2 diabetes (T2D) and are increasingly used for weight loss. Most high‐income countries subsidize access for T2D with restrictions; use outside of these restrictions occurs through private prescriptions. Despite strong consumer demand, the extent of private access to GLP‐1 medicines
Michael O. Falster, Juliana de Oliveira Costa, Tamara Y. Milder, Joanne Carson, Cade Shadbolt, Brendon L. Neuen, Clare Arnott, Andrew Wilson, Min Jun, Nicole Pratt, Sallie‐Anne Pearson   +10 more
wiley   +1 more source

Managing inventories for perishable e-groceries: The value of probabilistic information. [PDF]

PLoS One
Winkelmann D, Ulrich M, Römer M, Langrock R, Jahnke H.   +4 more
europepmc   +1 more source

Twenty years of inhaler therapy: A nationwide drug utilization study

British Journal of Clinical Pharmacology, EarlyView.
Aims This study aimed to map nationwide trends and prescribing patterns in inhaler use from 2004 to 2023. In light of evolving clinical guidelines and attention to the environmental impact of inhalers within recent years, we also examined variation in prescribing behaviour and patient‐level treatment choices. Methods Using nationwide health registries,
Katrine Bitsch Johansen, Lars Christian Lund, Zandra Nymand Ennis, Andrew Scourfield, Anders Løkke, Sidsel Arnspang Pedersen   +5 more
wiley   +1 more source

Using supermarket loyalty card data to investigate seasonal variation in laxative purchases in the UK. [PDF]

PLOS Digit Health
Burgess R, Poon N, Sloan E, Goulding J, Bould H, Skatova A.   +5 more
europepmc   +1 more source

Partners or passengers? Revisiting the association between diatoms and aquatic animals

Biological Reviews, EarlyView.
ABSTRACT Numerous studies have revealed the importance of research on the communities capable of colonizing animal surfaces (epibionts) and the animals on which they live (basibionts). Very few studies have considered epizoic diatoms, and there are gaps and biases in our knowledge, including the choice of basibionts, the methods used, and the habitats ...
Gianluca Vacca, Elisa Falasco, Francesca Bona   +2 more
wiley   +1 more source

Global pMDI Use and the Potential Impact of European PFAS Legislation on Access to These Essential Inhaled Medications. [PDF]

Pulm Ther
Kocks JWH, Harrison T, Bell JP, Rignall A, Khezrian M, Usmani OS.   +5 more
europepmc   +1 more source

A Business Framework for Product Take‐Back—A Structured Multiple‐Case Analysis

Business Strategy and the Environment, EarlyView.
ABSTRACT The potential of take‐back systems remains largely unrealized as initiatives have proven difficult to implement in practice. The question is why we do not see more take‐back systems given the substantial environmental benefits. We try to understand the challenges and stumbling blocks in setting up take‐back from a business perspective.
Rasmus Jørgensen, Torben Pedersen
wiley   +1 more source

Addressing lightning and market uncertainties in self-scheduling: A fuzzy-markov approach for smart grids. [PDF]

Sci Rep
Benistan IS, Shahbazzadeh MJ, Eslami M.
europepmc   +1 more source